9. The estimated base pay is $154,315 per year. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. ", Explore our career opportunities all over the world, We strive to attract the best people and create an environment that, Every world-class scientist or inspiring leader had to start somewhere, We value what you bring and believe you can successfully transfer it to a, As we age, the #immunesystem weakens making us more vulnerable to #infectiousdiseases. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. PO0487, Psychometric Properties of the SF-36 Vitality Scale ?in Patients With Anemia of Chronic Kidney Disease. Here at GSK, we unite science, technology and talent to get ahead of disease together. 1. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents ? Chapman KR, Bosnic-Anticevich S, Cano MC, et al. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. Trade marks are owned by or licensed to the GSK group of companies. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Obrador GT, et al. 801; Abstract A7738]. 5. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. [Poster No. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Schwarz TF et al. Dr. John Mascarenhas, a hematologist oncologist, explains what this condition is, how it presents and how it is diagnosed. P1483. 1. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma, 2. ORAL PRESENTATION: Kohli A, et al. GSK Medical Director Jobs | Glassdoor Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1?Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. 4. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. POSTER: Trennery CL, Martin S, Kosa K, et al. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. 1-800-822-7967. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1?specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. [Poster No. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial? Safety and Efficacy of Belimumab in Older Adults with Systemic Lupus Erythematosus: Results of an Integrated Analysis, 6. 1. Search job openings, see if they fit - company salaries, reviews, and more posted by GSK employees. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Strobel M, Alves D, Roufosse F, et al. Singh, AK et al. (Poster No. GSK's Dr. Len Friedland, VP and Director of Scientific Affairs and Public Health for Sideline RSV Behind the science Oncology Gaining a deeper understanding of myelofibrosis - a rare blood cancer. Bring your unwanted, unused, and expired medicines to the 24th@DEAHQQ's National Prescription Drug#TakeBackDayy between 10AM - 2PM. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. 2015;21(8):914-921. 2. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Other market sites can be reached by visiting our location selector. 4. Wechsler M, Kovalszki A, J Silver, et al. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), 4. to let us know you're having trouble. . Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. POSTER: Healthcare Costs in Patients With Newly Diagnosed Advanced Ovarian Cancer Receiving Maintenance Treatment With Niraparib Monotherapy Or Active Surveillance In The United States, 2. Strong industry experience, spanning clinical development and medical affairs. , Have you heard of #myelofibrosis, a rare form of blood cancer? 1. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. Ison MG et al. This site is intended for US healthcare professionals only. signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. © 2022 GSK group of companies or its licensor. Affairs portal to a separate website maintained by 1. 1. 2017;276(1):97-111. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States (ESGO Encore), 3. 61), 1. 2018;7(5):e1426519. Sign In. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. 8. 13. Get notified about new Gsk Medical Affairs jobs in United States. 5. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. 3. Learn how to prepare, what will be collected, and how to safely store your medicine until the event at: Information Database, Vaccine Temperature Poster No. Corbridge T, Deb A, Germain G, et al. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. 10. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. 1090; Abstract A3325]. 1. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Gsk Medical Affairs Jobs in United States, Director of Medical and Clinical Affairs for Flu/COVID-19 Vaccines, Director, US Medical Affairs, Scientific Affairs and Public Health, Director, Vaccines Scientific Communications, ViiV (GSK) Global Medical Affairs Director, Field Based Medical Science Liaison- IL/MI, Vaccine Development Leader (VDL), MAPS Vaccine, Global Regulatory Affairs Manager, Labelling, Director, Independent Medical Education (IME) & Grants, US Medical Affairs Scientific Director, Specialty Pipeline, ViiV (GSK) Director, Community Medical Liaison, Community Engagement Specialist HIV Prevention, Global Medical Affairs Director - Neurosciences. Paclitaxel Versus Placebo + Carboplatin?Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. [Oral presentation available here; Abstract A4212]. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. Fiore. The information is not intended as medical advice. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. GSK is an Equal Opportunity/Affirmative Action Employer. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. Johansen K, et al. peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world's health. Ismaila A, Haeussler K, Czira A, et al. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Singh AK, et al. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. Strobel MJ, Alves D, Roufosse F, et al. 3. Hemoglobin Stability in the ASCEND-D and ND trials. Click the link in the email we sent to to verify your email address and activate your job alert. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. GSK Medical Affairs Jobs | Glassdoor Slade D, Ray R, Moretz C, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. GSK Global Medical Affairs Lead Jobs | Glassdoor Kerstjens HA, Pavord ID, Peachey G, et al. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. The estimated total pay for a Medical Science Liaison at GSK is $234,850 per year. Aydanos a proteger Glassdoor verificando que eres una persona real. Bell CF, Blauer-Peterson C. Singh AK, et al. Thomas R, Al-Khadairi G, Roelands J, et al. There is always room to grow as a professional and own your career path. [Poster No. 340), 1. 1. Lee J, Pollard S, Liu M, et al. Poster No. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. J Clin Invest. P1091; Abstract A3326]. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. NY-ESO-1 and LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Psychometric Properties of the SF-36 Vitality Scale ?in Patients With Anemia of Chronic Kidney Disease. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. 2001-2023 GSK plc. ORAL PRESENTATION: OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis, 2. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. Nonclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. Oral presentation. Pollard S, Offenberger J, Lee FE-H, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. P742; Abstract A4771]. O?Connor BP, Raman VS, Erikson LD, et al. GSK values your privacy and your trust is important to us. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Blood. POSTER: Phase 2 study of anti-TIGIT GSK4428859A (GSK?859A)/EOS-448 + anti-CD96 GSK6097608 (GSK?608) + anti?PD-1 dostarlimab in non-small cell lung cancer (NSCLC), 1.POSTER: Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French Sarcoma Group (Presentation Posted With Permission), 1.POSTER: NIRVANA-1: A multicentric randomized trial to compare carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP?bevacizumab (bev) followed by nira-bev in patients with stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery (Presentation Posted With Permission), 1. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Insights From Allergy Practice (Poster No. Review the package insert for important safety information. Genes Dev. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. 21. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 4. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-? Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. 1. Benefit?risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. 8. Si vous continuez voir ce POSTER: Differentiation of Niraparib and Olaparib Brain Penetration in Healthy Rhesus Macaque Monkeys, 5. For roles at the vice president level and above, we expect an ethnically diverse representation of at least 30% by 2025. Herrera-Restrepo O et al. 817; Abstract A4306]. 8. Us. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis, 2. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Poster No. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer (ESGO Encore), 1. Lu E, et al. Bogart M, Han X, Bengtson L, et al. For our most senior roles we start with a diverse shortlist of qualified candidates, including ethnically diverse representation (defined by country). Search jobs | GSK POSTER: Differentiation of Niraparib and Olaparib Brain Penetration in a Mouse Brain Metastatic Tumor, 4. GSK Medical Director, Global Medical Affairs - Rheumatology Collegeville, PA 11d $133K-$225K Per Year (Glassdoor est.) P1505. Apply to Public Health Nurse, Medical Director, Senior Director and more! and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. P1512. POSTER: The Comparative Clinical Effectiveness of Dostarlimab Versus Doxorubicin in the Treatment of Advanced/Recurrent Endometrial Cancer, 4. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Our employees and our values are at the heart of everything we do. 5. POSTER: Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first-line maintenance therapy, 1. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Zejula [summary of product characteristics]. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. Further details on cookies and how to object to their placement can be found in our Cookie Policy. When expanded it provides a list of search options that will switch the search inputs to match the current selection. 6. Domingo Ribas C, Pavord I, Price R, et al. Cho E-Y, Lee E-B, Yang S-H, et al. 115 Medical Affairs Gsk jobs available on Indeed.com. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. 2. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. Nathan R, Boulet L-P, Kerstjens HA, et al. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. We are led by our purpose: to get ahead of disease together. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. CD8?-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Kickstart your career at GSK by applying to any one of our Early Talent Programmes programmes. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448) Goodall E, Wood R, Numbere B, et al. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. 811; Abstract A4300]. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. 1. Patients with Uncontrolled Asthma Eligible for a Biologic. Watch the video here: gsk.to/3KQpI7P, Today is the day! 3. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment? Singh, AK et al. Experienced professionals | GSK 3. Ismaila A, Haeussler K, Czira A, et al.
How Did Knights Wear Their Hair,
Fort Worth City Council Members Party Affiliation,
Gary Carpenter Obituary,
Was I Sexually Abused Quiz,
Articles G